Pharma Update
Adding to in-house opportunities through BD
Successful track record of disrupting the SoC and building new franchises
Zilebesiran (siRNA targeting AGT)
Our proven strengths
Roche
No AGT
synthesis
3
AGT
Zilebesiran
Renin
Angl
ACE
Angli
Aldosteron
Strong track record of entering new therapeutic areas and disrupting
*** established markets
Expertise in advancing inclusive research to address health equity in
CVM
ABPM
ABPM
⚫ siRNA targeting AGT, the precursor protein of all angiotensin peptides
.
Consistent + durable BP control with potential for improved adherence
⚫ Ph II (KARDIA-1/2) development program ongoing; positive KARDIA-1 results
to be presented at upcoming scientific conference; KARDIA-2 data
expected in early 2024
Strong Pharma & Diagnostics partnerships with health systems allow
for integrated disease management solutions
Integrated commercialization expertise utilizing an innovative
customer engagement model
Prowess in access and policy shaping differentiates Roche in the
industry
In collaboration with Alnylam Pharmaceuticals
siRNAi-small interfering RNA; AGT-angiotensinogen; SoC-standard of care; CVM-cardiovascular & metabolism; BP=blood pressure
65View entire presentation